Laura Stoppel
Directeur/Membre du Conseil chez ACUMEN PHARMACEUTICALS, INC.
Profil
Dr. Laura Stoppel is an Independent Director at Acumen Pharmaceuticals, Inc., an Independent Director at Artiva Biotherapeutics, Inc. and a Principal at RA Capital Management LP.
She is on the Board of Directors at International Rett Syndrome Foundation, Indapta Therapeutics, Inc., Acumen Pharmaceuticals, Inc., Nimbus Therapeutics LLC and Artiva Biotherapeutics, Inc. Dr. Stoppel was previously employed as a Principal by RA Capital Management LP (Private Equity).
She received her undergraduate degree from Harvard University and a doctorate degree from Massachusetts Institute of Technology.
Postes actifs de Laura Stoppel
| Sociétés | Poste | Début |
|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/11/2020 |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/06/2020 |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/10/2020 |
Indapta Therapeutics, Inc.
 Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | 01/01/2022 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Gestionnaire de Portefeuille-Actions | 01/12/2020 |
| International Rett Syndrome Foundation | Directeur/Membre du Conseil | 01/07/2023 |
Anciens postes connus de Laura Stoppel
| Sociétés | Poste | Fin |
|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Analyste en capital-investissement | 01/12/2020 |
Formation de Laura Stoppel
| Harvard University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA. | Health Technology |
Nimbus Therapeutics LLC
Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Indapta Therapeutics, Inc.
Indapta Therapeutics, Inc. BiotechnologyHealth Technology Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX. | Health Technology |
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Finance |
| International Rett Syndrome Foundation |
